Abstract:Abstract Introduction Treatment of erectile function (EF) in men with type 2 diabetes (T2DM) remains challenging. EF and sexual activity contribute to quality of life (QoL) in aging men. Objective to investigate effects of long-term TTh up to 13 years in men with hypogonadism and T2DM compared to an untreated control group. Methods In an ongoing registry study in men with hypogonadism (total testosterone ≤350 ng/mL and at least moderate symptoms on the Aging Males’ Symptoms scale, AMS) in a single urology office, 370 men had type 2 diabetes. 190 men received testosterone undecanoate (TU) injections 1000 mg/12 weeks following an initial 6-week interval (T-group), 180 opted against TTh and served as controls (CTRL). IIEF-EF (5+1 questions, maximum score: 30) and AMS were assessed at each visit. Patients were asked at each visit about sexual activity per month. Absolute measures with standard deviations (SDs) as well as changes over time, adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids, and quality of life to account for baseline differences between groups, are reported for a duration of 13 years. Results Mean (median) follow-up: T-group 9.0±3.4 (9), CTRL 9.7±3.2 (11) years, total observation time: T-group 1703, CTRL 1747 patient-years. Baseline age was 60.0±6.4 (T-group) and 63.0±4.9 years (CTRL) (p<0.0001). 71 patients (37.4%) in the T-group and 74 (41.1%) in CTRL had a history of cardiovascular disease (myocardial infarction MI, stroke, or coronary artery disease diagnosis) (p<0.05). Baseline smoking prevalence was 41.6% (79 men) in the T-group and 37.4% (67 men) in CTRL (p=0.415). At baseline, PDE5-Inhibitors were used by 29.5% (T-group) and 35.0% (CTRL) (p=0.255). T-group: IIEF-EF increased from 15.8±6.0 (means ± SD) at baseline to 29.5±0.9 after 13 years. Changes: IIEF-EF increased by 12.1±0.3 (least squares means ± standard errors) in year 13, p<0.0001 vs. baseline. CTRL: IIEF-EF decreased from 19.2±3.8 at baseline to 6.9±1.0 after 13 years. Changes: IIEF-EF declined by 14.7±0.3 after 13 years. T-group: sex frequency increased from 3.4±1.3 (means ± SD) at baseline to 12.0±5.4 after 13 years. Changes: sex frequency increased by 6.6±0.5 (least squares means ± standard errors) in year 13, p<0.0001 vs. baseline. CTRL: sex frequency decreased from 7.7±3.4 at baseline to 0.0±0.2. Changes: sex frequency declined by 10.5±0.5 (p<0.0001). T-group: AMS decreased from 55.3±9.3 (means ± SD) at baseline to 17.1±0.2 after 13 years. Changes: AMS decreased by 31.4±0.7 (least squares means ± standard errors) in year 13, p<0.0001 vs. baseline. CTRL: AMS increased from 40.1±5.7 at baseline to 65.8±4.6 after 13 years. Changes: AMS increased by 25.8±0.7. Conclusions Long-term TTh in men with type 2 diabetes improved erectile function, sexual activity, and QoL despite advancing age. In the untreated control group, sexual function and QoL deteriorated progressively. Disclosure Yes, this is sponsored by industry/sponsor: Bayer AG, Berlin, Germany Clarification Industry funding only - investigator initiated and executed study Any of the authors act as a consultant, employee or shareholder of an industry for: Bayer AG, Berlin, Germany

409-P: Long-Term Testosterone Treatment Improves Estimated Glomerular Filtration Rate (eGFR) in Men with Hypogonadism and Type 2 Diabetes Mellitus: Update of Registry Data

416-P: Mortality, Major Adverse Cardiovascular Events (MACE) and Diabetic Complications in Men with Hypogonadism and Type 2 Diabetes on Long-Term Testosterone Treatment: An Update from a Urological Registry Study

819-P: Long-Term Testosterone Treatment Improves Liver Function Parameters in Men with Hypogonadism and Type 2 Diabetes Mellitus: Real-World Data from a Registry

Improved glycaemic control and reduced incidence of myocardial infarctions, strokes, and mortality in men with hypogonadism and type 2 diabetes, with and without long-term testosterone therapy

820-P: Testosterone Treatment Improves Glycemic Control and Leads to Remission in 56.8% of Patients with Hypogonadism and Type 2 Diabetes (T2DM) : Update of Real-World Data from a Registry Study

(076) Effects of Long-term Testosterone Therapy on Erectile Function, Sexual Activity, and Quality of Life in Hypogonadal Men with Type 2 Diabetes – Results from a Registry Study

1427-P: Long-Term Treatment with Testosterone Leads to Profound Weight Loss in Men with Hypogonadism and Type 2 Diabetes: Update of Real-World Data from a Registry Study

Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study

Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study

Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus

PMON264 TESTOSTERONE IMPROVES QUALITY OF LIFE, SEXUAL FUNCTION AND DELAYED VERBAL RECALL- RANDOMISED PLACEBO-CONTROLLED STUDY IN HYPOGONADAL MEN WITH UNCONTROLLED TYPE 2 DIABETES – STRIDE STUDY

Testosterone treatment, weight loss and health-related quality of life and psychosocial function in men: a two-year RCT

Testosterone undecanoate is associated with improved ageing male symptoms score in men with type 2 diabetes and adult-onset testosterone deficiency: re-analyzed results from a randomised controlled trial

Effect of testosterone undecanoate on sexual functions, glycaemic parameters, and cardiovascular risk factors in hpogonadal men with type 2 diabetes mellitus

Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism

Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial

RF34 | PMON263 Study of Testosterone Replacement in Hypogonadal Men With Uncontrolled Type 2 Diabetes – a Randomised Double Blinded Placebo Controlled Trial (STRIDE Study)

OR29-4 Prevention of Type 2 Diabetes by Testosterone in the T4DM Trial: Analysis of Effect Mediation

Testosterone therapy in older men: clinical implications of recent landmark trials

Testosterone therapy in men with classical versus functional hypogonadism: results from a controlled 9‐years, real‐world registry study

PMON265 First Ever Placebo-Controlled Randomised Study of Testosterone on Ambulatory Blood Pressure and Heart Rate in Hypogonadal Men With Uncontrolled Type 2 Diabetes – STRIDE Study